Nanologica

0.90 SEK

-0.22 %

Less than 1K followers

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-0.22 %

-29.57 %

-28.73 %

-14.07 %

-50.66 %

-49.41 %

-90.43 %

-92.17 %

-95.05 %

Nanologica is a life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially designed for the purification of peptide drugs, such as insulin and GLP-1 analogs. Nanologica operates in a global niche market for medicines for the treatment of diabetes and obesity. Nanologica was founded in 2004 and has its headquarters in Södertälje.

Market cap

79.36M SEK

Turnover

41.66K SEK

Revenue

14.54M

EBIT %

-407.57 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2

2026

Annual report '25

23.4

2026

Interim report Q1'26

21.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release11/28/2025, 9:21 AM

Nanologica AB (publ) Receives Order of SEK 1.5 Million on a New Product

Press release10/24/2025, 7:13 AM

Redeye: Nanologica (Q3 update) - Production check, now positioned for ramp up

Regulatory press release10/23/2025, 6:10 AM

Interim Report Q3 2025 Nanologica AB (publ)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release10/22/2025, 7:41 AM

Nanologica AB (publ) Receives Order of appx. SEK 1 Million In China

Regulatory press release10/16/2025, 2:34 PM

Nanologica AB (publ) Receives Additional Order of approx. SEK 2.7 Million from Customer in the US

Regulatory press release10/14/2025, 9:53 AM

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

Regulatory press release10/1/2025, 7:55 AM

Nanologica AB (publ) Enters the Insulin Market in China

Press release7/11/2025, 9:57 AM

Redeye: Nanologica Q2 2025 - Low near-term visibility but encouraging long-term case

Regulatory press release7/10/2025, 6:10 AM

Interim Report Q2 2025 Nanologica AB (publ)

Regulatory press release6/30/2025, 9:00 AM

Number of Shares and Votes in Nanologica AB (publ)

Regulatory press release6/13/2025, 8:34 AM

STATEMENT FROM THE BOARD OF DIRECTORS OF NANOLOGICA AB (PUBL) REGARDING THE MANDATORY BID FROM FLERIE INVEST AB

Regulatory press release6/12/2025, 6:14 AM

NANOLOGICA AB (PUBL) RECEIVES ORDER OF APPX. SEK 1.3 MILLION FROM NEW CUSTOMER IN THE US

Regulatory press release5/23/2025, 2:41 PM

Nanologica AB (publ) Announces the Outcome of the Exercise of Warrants of Series TO5

Regulatory press release5/23/2025, 5:36 AM

Comment from the Board of Nanologica AB (publ) Regarding the Mandatory Bid from Flerie Invest AB

Regulatory press release5/22/2025, 12:54 PM

Bulletin from the AGM 2025 Nanologica AB (publ)

Press release4/26/2025, 9:42 AM

Nanologica AB Informs that Flerie Invest AB has Passed the Threshold for Mandatory Bid

Press release4/24/2025, 11:36 AM

Redeye: Nanologica Q1 2025 - Limited near-term visibility but sales ramp up to be expected in H2

Regulatory press release4/23/2025, 5:06 AM

Nanologica AB Receives Order Worth USD 180,000 from New Customer in China

Regulatory press release4/16/2025, 3:35 PM

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

Regulatory press release4/16/2025, 6:12 AM

Interim Report Q1 2025 Nanologica AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.